Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12768
Abstract: Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging,… read more here.
Keywords: myelodysplastic syndromes; candidate biomarker; bone marrow;
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24746
Abstract: Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are… read more here.
Keywords: myelodysplastic syndromes; risk; lower risk; bortezomib ... See more keywords
Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24779
Abstract: [1] Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90: 831–841. [2] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification… read more here.
Keywords: myelodysplastic syndromes; brazil retrospective; lymphocytic leukemia; leukemia brazil ... See more keywords
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24930
Abstract: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and… read more here.
Keywords: syndromes 2018; myelodysplastic syndromes; risk; diagnosis risk ... See more keywords
Allogeneic stem cell transplantation for patients with myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26763
Abstract: Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem cell neoplasms primarily affecting older persons, associated with dysplastic changes of bone marrow cells, peripheral cytopenias, and various risk of leukemic transformation. Although treatment… read more here.
Keywords: myelodysplastic syndromes; treatment; transplantation; stem cell ... See more keywords
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26771
Abstract: Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there… read more here.
Keywords: myelodysplastic syndromes; relapsed refractory; venetoclax azacitidine; phase study ... See more keywords
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26812
Abstract: Several editions of the World Health Organization (WHO) classifications of lympho‐hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for diagnosis. Since the 4th WHO edition, here referred as WHO‐HAEM4, significant clinico‐pathological,… read more here.
Keywords: myelodysplastic syndromes; acute myeloid; 5th edition; international consensus ... See more keywords
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30532
Abstract: Myelodysplastic syndromes (MDS) are genetically, biologically, and clinically very heterogeneous. Although allogeneic stem cell transplantation (alloSCT) remains the only intervention with a potential for cure, less than 5% of patients undergo transplantation because of age… read more here.
Keywords: myelodysplastic syndromes; histone deacetylase; higher risk; hypomethylating agents ... See more keywords
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30917
Abstract: The karyotype of bone marrow cells at the time of diagnosis is a strong prognostic parameter for overall survival as well as acute myeloid leukemia (AML) progression in patients with myelodysplastic syndromes (MDS). However, to… read more here.
Keywords: clonal evolution; myelodysplastic syndromes; cytogenetic clonal; syndromes associated ... See more keywords
Iron overload in patients with myelodysplastic syndromes: An updated overview
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31550
Abstract: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by a broad clinical spectrum related to ineffective hematopoiesis leading to unilineage or multilineage cytopenias, with a high propensity for transformation… read more here.
Keywords: overload patients; myelodysplastic syndromes; patients mds; iron overload ... See more keywords
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33745
Abstract: SF3B1 mutations (SF3B1mut) in myelodysplastic syndromes (MDS) frequently involve codon K700E and have a favorable prognosis. The prognostic effect of non‐K700E SF3B1mut is uncertain. read more here.
Keywords: myelodysplastic syndromes; mutation involving; sf3b1 mutation; independently predicts ... See more keywords